Author

Paula Muñoz Romero

Observed name: P. Romero

Institution: Menarini Group (Italy)

Observed institution: Menarini Group (Italy)

ORCID: 0009-0007-6480-4111

Observed ORCID: 0009-0007-6480-4111

OpenAlex ID: A5113239109

Elacestrant in various combinations in patients (pts) with estrogen receptor-positive (ER+), HER2-negative (HER2-) locally advanced or metastatic breast cancer (adv/mBC): Preliminary data from ELEVATE, a phase 1b/2, open-label, umbrella study.

2024 · Hope S. Rugo, Joyce O'Shaughnessy, et al. · Journal of Clinical Oncology · 9

Abstract RF7-01: Elacestrant in combination with everolimus or abemaciclib in patients with ER+/HER2- locally advanced or metastatic breast cancer (mBC): phase 2 results from ELEVATE, an open-label, umbrella study

2026 · H. Rugo, S. M. Tolaney, et al. · Clinical Cancer Research · 5

Elacestrant combinations in patients (pts) with ER+/HER2- locally advanced or metastatic breast cancer (mBC): Safety update from ELEVATE, a phase (Ph) 1b/2, open-label, umbrella study.

2025 · Nancy Chan, Virginia G. Kaklamani, et al. · Journal of Clinical Oncology · 4

Elacestrant (Ela) combinations with ribociclib (Ribo) and everolimus (Eve) in patients (pts) with ER+/HER2- locally advanced or metastatic breast cancer (mBC): Update from ELEVATE, a phase (Ph) 1b/2, open-label, umbrella study.

2025 · Hope S. Rugo, Sara M. Tolaney, et al. · Journal of Clinical Oncology · 4

Elacestrant in Combination with Everolimus for Estrogen Receptor–Positive, HER2-Negative Previously Treated Advanced Breast Cancer: Results from ELEVATE

2026 · Hope S. Rugo, Sara M. Tolaney, et al. · Clinical Cancer Research · 2

Abstract PS7-07: Elacestrant plus abemaciclib (abema) combination in patients (pts) with estrogen receptor-positive (ER+), HER2-negative (HER2-) advanced or metastatic breast cancer (mBC)

2025 · Hope S. Rugo, Sara M. Tolaney, et al. · Clinical Cancer Research · 1

Elacestrant in combination with capivasertib in patients with ER+/HER2− advanced breast cancer: Update from ELEVATE, a phase 1b/2, open-label, umbrella study.

2026 · Wassim McHayleh, Sara M. Tolaney, et al. · Journal of Clinical Oncology

Abstract CT262: Elacestrant (Ela) in combination with everolimus (Eve) or abemaciclib (Abema) in patients with ER+/HER2- locally advanced or metastatic breast cancer mBC: phase 2 results from ELEVATE, an open-label, umbrella study

2026 · Hope S. Rugo, Sara M. Tolaney, et al. · Cancer Research

Abstract PS7-06: Elacestrant combinations in patients with estrogen receptor-positive (ER+), HER2-negative (HER2-) locally advanced or metastatic breast cancer (mBC): Update from ELEVATE, a phase 1b/2, open-label, umbrella study

2025 · Hope S. Rugo, Sara M. Tolaney, et al. · Clinical Cancer Research

Works count: 9

Citation count: 25

H-index: 4

I10-index: